Bliss GVS Pharma Ratios

Bliss GVS Pharma Ltd Ratios

The Bliss GVS Pharma Ltd Ratios page provides a complete fundamental analysis of Bliss GVS Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Bliss GVS Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Bliss GVS Pharma Ltd (NSE: BLISSGVS, BSE: 506197) is currently trading at ₹216.26, with a market capitalization of ₹23.56B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Bliss GVS Pharma Ltd remains a key stock for fundamental analysis using Bliss GVS Pharma Ltd Ratios.

Bliss GVS Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Bliss GVS Pharma Ltd P/E ratio currently stands at 14.79, making it one of the most tracked metrics in Bliss GVS Pharma Ltd Ratios.

Historically, the Bliss GVS Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 14.79
• 2023: 15.84
• 2022: 10.61
• 2021: 53.82
• 2020: 15.20

The decline in Bliss GVS Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Bliss GVS Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.18.

Historical P/B trend:

• 2024: 1.18
• 2023: 1.22
• 2022: 0.84
• 2021: 0.97

Bliss GVS Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Bliss GVS Pharma Ltd P/S ratio currently stands at 1.55, an important part of Bliss GVS Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.55
• 2023: 1.56
• 2022: 1.01
• 2021: 1.10

A stable or declining Bliss GVS Pharma Ltd P/S ratio indicates cautious market sentiment.

Bliss GVS Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Bliss GVS Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 10.79.

Historical Bliss GVS Pharma Ltd Price to Cash Flow Ratio:

• 2024: 10.79
• 2023: 11.75
• 2022: 18.22
• 2021: 5.85
• 2020: 16.52

The declining Bliss GVS Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Bliss GVS Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Bliss GVS Pharma Ltd EV currently stands at ₹11.63B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 11.63B
• 2023: 11.14B
• 2022: 7.79B
• 2021: 7.69B

Bliss GVS Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Bliss GVS Pharma Ltd EV/EBITDA ratio is currently 9.46, a key metric in Bliss GVS Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 9.46
• 2023: 7.45
• 2022: 6.68
• 2021: 6.85

Higher Bliss GVS Pharma Ltd EV/EBITDA suggests premium valuation.

Bliss GVS Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Bliss GVS Pharma Ltd D/E ratio is currently 0.08, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.08
• 2023: 0.10
• 2022: 0.12
• 2021: 0.13

Bliss GVS Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Bliss GVS Pharma Ltd ROE currently stands at 8.36%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 8.36
• 2023: 8.15
• 2022: 8.32
• 2021: 1.85

Declining ROE indicates pressure on profitability.

Bliss GVS Pharma Ltd Ratios Analysis Summary

The Bliss GVS Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Bliss GVS Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Bliss GVS Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.